4SC positive on resminostat cancer trials
This article was originally published in Scrip
Executive Summary
German biotechnology firm 4SC has presented new positive data from two ongoing open-label Phase I/II trials of its oral pan-histone deacetylase (HDAC) inhibitor, resminostat, in hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) respectively.